Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc

Southland stock was up on Friday after the company announced new construction contracts.


Why Is Penny Stock Southland (SLND) Up Today?

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Arhaus (ARHS) and Stella International Hold...

Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: Arhaus (ARHS) and Stella International Holdings Limited (OtherSLNLF)

The latest announcement is out from Soluna Holdings ( ($SLNH) ). In 2026, Soluna Holdings, Inc. converted all 62,500 outstanding shares of its Seri...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$10.50	-3.85%	277.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$10.50	-3.8%	277.23K
3
4
5
6

SLN

SLN

Get Silence Therapeutics Plc Data in Excel

Get Silence Therapeutics Plc Data in Excel